1425378-01-3

Upstream product

• 1425377-88-3 (3R,4R,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-1-((4-methoxybenzyl)oxy)-3-((2-naphthylmethyl)oxy)piperidine 
• 1425377-62-3 (1R,2R,5R)-2-(benzyloxy)-1-((2-naphthylmethyl)oxy)-5-((benzyloxy)methyl)cyclopent-3-ene 
• 1425377-60-1 (1R,2R,3R,4R)-4-(benzyloxy)-2-((benzyloxy)methyl)-3-((2-naphthylmethyl)oxy)cyclopentyl methanesulfonate 
• 1353742-20-7 (1R,2R,3R,4R)-4-(benzyloxy)-2-((benzyloxy)methyl)-3-hydroxycyclopentyl methanesulfonate 
• 100-51-6 benzyl alcohol 

Downstream Products

• 1425378-08-0 C₅₉H₆₁NO₁₀ 

Relevant academic research and scientific papers

N-O bond as a glycosidic-bond surrogate: Synthetic studies toward polyhydroxylated N-alkoxypiperidines

A series of novel polyhydroxylated N-alkoxypiperidines has been synthesized by ring-closing double reductive amination (DRA) of highly functionalized 1,5-dialdehydes with various hydroxylamines. The required saccharide-based dialdehydes were prepared efficiently from sodium cyclopentadienylide in seven steps. A two-step protocol has been developed for the DRA; it led, after deprotection, to isofagomine, 3-deoxyisofagomine, and numerous other N-alkoxy analogues. The barrier to inversion in these polyhydroxylated N-alkoxypiperidine derivatives was found by variable-temperature NMR methods to be approximately 15 kcal mol-1. With the exception of N-hydroxyisofagomine itself, none of the compounds prepared showed significant inhibitory activity against sweet almond β-glucosidase. Copyright